Monkeypox (mpox) Diagnosis Market Size, Share, and Growth Forecast 2026 - 2033

The global Monkeypox (mpox) Diagnosis market size is expected to be valued at US$ 2.2 billion in 2026 and projected to reach US$ 3 billion, growing at a CAGR of 4.7% between 2026 and 2033. The market is experiencing significant growth due to the increasing incidence of Mpox outbreaks and the emphasis on infectious disease surveillance worldwide.

Growing awareness among healthcare providers and public health authorities has accelerated the adoption of advanced diagnostic technologies, particularly molecular testing methods such as PCR and RT-PCR. Governments and healthcare organizations are investing in laboratory infrastructure, outbreak preparedness, and disease monitoring programs to improve early detection and containment.

Drivers - Rising Global Mpox Outbreaks and WHO Emergency Declarations

The resurgence of mpox across multiple continents has been the single most powerful catalyst for diagnostic demand. In 2022, the WHO reported over 87,000 confirmed cases in more than 110 countries a stark departure from the disease's historically endemic African geography. The emergence of clade Ib in the Democratic Republic of Congo (DRC) in 2024, which prompted the WHO to re-declare a PHEIC, further intensified procurement of diagnostic kits by national public health authorities. Governments across Europe, North America, and Asia-Pacific fast-tracked laboratory preparedness funding, directly translating into increased orders for PCR Test Kits, Rapid Antigen Test Kits, and associated instruments, sustaining robust market momentum.

Expanding Molecular Diagnostics Infrastructure and Regulatory Approvals

Strategic investments in molecular diagnostics capacity across both developed and emerging economies are reinforcing market growth. The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to multiple mpox PCR assays including those from Laboratory Corporation of America (LabCorp) and Quest Diagnostics enabling rapid deployment across clinical settings. Simultaneously, the European Centre for Disease Prevention and Control (ECDC) published technical guidance on orthopoxvirus testing protocols, encouraging member states to upgrade diagnostic platforms. The proliferation of real-time PCR (RT-PCR) instruments with multiplex capabilities and the integration of digital pathology workflows are enabling higher sample throughputs, reducing per-test costs, and making confirmatory diagnosis more accessible across diverse healthcare settings globally.

Restraints - Infrastructural Gaps in Low-Income and Endemic Regions

Despite rising demand, significant infrastructural gaps persist in sub-Saharan Africa historically the most affected region. According to the Africa Centres for Disease Control and Prevention (Africa CDC), fewer than 40% of African Union member states possessed adequate BSL-2 laboratory capacity for routine orthopoxvirus testing as of 2023. Cold-chain dependencies, unreliable electricity supplies, and limited trained biomedical personnel constrain effective deployment of sophisticated PCR platforms, resulting in significant underdiagnosis and limiting addressable market potential in these high-burden geographies.

High Cost of Advanced Diagnostic Instruments and Limited Reimbursement

Capital expenditure requirements for advanced instruments and analyzers used in mpox diagnosis remain a material barrier to broader adoption. Automated real-time PCR systems can cost between US$ 20,000 and US$ 80,000 per unit, placing them beyond the procurement reach of many resource-limited public health laboratories. Furthermore, inconsistent and often absent reimbursement frameworks for mpox testing in middle-income countries add to cost pressures. The Centers for Disease Control and Prevention (CDC) in the U.S. noted reimbursement ambiguity as a friction point for commercial laboratories adopting mpox testing panels, constraining service expansion and limiting market penetration for higher-value diagnostic products.

Opportunities - Emergence of Point-of-Care Rapid Antigen Testing Platforms

The development and commercialization of point-of-care (POC) rapid antigen tests for mpox represent a transformative opportunity for market participants. The WHO in 2023 issued a target product profile (TPP) for mpox rapid diagnostics, prioritizing sensitivity thresholds of ≥80% and specificity of ≥97% for antigen-based tests deployable at or near the patient. Companies that develop WHO-prequalified POC tests will unlock procurement pathways through UNICEF and the Global Fund, addressing demand across Africa and Southeast Asia.

The accessibility of low-cost, equipment-free antigen tests can dramatically extend diagnostic reach to primary care clinics, mobile health units, and community settings, enabling earlier case isolation, contact tracing, and outbreak containment driving substantial volume-based revenue growth for diagnostics manufacturers.

Genomic Surveillance and Next-Generation Sequencing Integration

Genomic surveillance of mpox variants is gaining traction as a public health priority, creating a high-value opportunity for sequencing instrument and reagent vendors. The Global Initiative on Sharing All Influenza Data (GISAID) platform expanded to cover mpox had received over 5,000 mpox genome sequences from more than 60 countries by mid-2024, reflecting growing national commitment to sequencing-based surveillance. Integration of next-generation sequencing (NGS) workflows into mpox diagnosis pipelines, particularly for clade differentiation (clade I vs. clade II) is generating demand for premium reagents, library preparation kits, and bioinformatics platforms. This represents a high-margin, differentiated segment, particularly for manufacturers able to pair wet-lab sequencing consumables with validated mpox variant interpretation software.

Product Type Insights

PCR Test Kits command  32% of the global mpox diagnosis market in 2026, establishing them as the dominant product segment. The primacy of PCR reflects its status as the gold-standard method endorsed by the WHO and CDC for confirmatory mpox diagnosis, owing to its superior analytical sensitivity (limit of detection as low as 10–100 genome copies/reaction) and specificity for orthopoxvirus DNA. Public health laboratories across North America and Europe adopted PCR-based mpox testing panels rapidly during the 2022 outbreak, institutionalizing the technology. Continued rollout of laboratory-developed PCR tests (LDTs) and commercially authorized kits in hospital and reference laboratory settings will sustain this segment's leadership.

Application Insights

Clinical diagnostics constitutes the leading application segment, accounting for  48% of market revenue in 2026. This dominance is driven by the direct and immediate need for patient-level confirmation of mpox infection to guide clinical management, isolation decisions, and antiviral therapy eligibility. Hospitals, infectious disease clinics, and sexual health centers key clinical care points require reliable and rapid test results to reduce diagnostic delays. The European Centre for Disease Prevention and Control (ECDC) recommended enhanced clinical diagnostic capacity across member states during the 2022–2024 outbreak waves, substantially increasing kit procurement volumes by clinical laboratories. As mpox co-infections with other STIs (sexually transmitted infections) rise, clinical diagnostic testing volume is expected to grow further.

End-user Insights

Public health laboratories represent the leading end-use segment, capturing an estimated 38% market share in 2026. These facilities operated by national public health agencies such as the U.S. CDC, Public Health England (UKHSA), and Institut Pasteur serve as primary confirmatory testing hubs during outbreak responses and maintain permanent preparedness capacities. Bulk procurement frameworks, emergency use designations, and dedicated outbreak response budgets give public health laboratories both purchasing power and reliability as a revenue base. Government-funded surveillance programs ensure consistent demand for PCR platforms, sequencing reagents, and consumables, reinforcing segment leadership across all major regions.

North America Monkeypox (mpox) Diagnosis Market Trends and Insights

North America holds the leading position in the global mpox diagnosis market with 37% revenue share in 2026. The region benefits from robust public health infrastructure, rapid FDA Emergency Use Authorization pathways, high laboratory testing density, and strong government procurement through agencies such as the CDC and the Biomedical Advanced Research and Development Authority (BARDA), ensuring sustained demand for advanced mpox diagnostics.

U.S. Monkeypox (mpox) Diagnosis Market Size

The United States accounts for  85% of the North American mpox diagnosis market. The country reported over 32,000 confirmed cases during the 2022 outbreak, driving massive expansion in commercial laboratory testing capacity. BARDA investments in diagnostic readiness and ongoing CDC laboratory preparedness programs underpin continued market growth.

Europe Monkeypox (mpox) Diagnosis Market Trends and Insights

Europe represents the second-largest regional market, supported by the ECDC's coordinated laboratory response network and strong public health testing mandates. EU member states demonstrated rapid capacity scale-up during the 2022 outbreak, with national reference laboratories anchoring the diagnostic ecosystem. Ongoing investment in preparedness infrastructure and genomic surveillance programs is sustaining steady demand across Western and Northern European markets.

Germany Monkeypox (mpox) Diagnosis Market Size

Germany accounts for a 22% of the European mpox diagnosis market, reflecting its dense laboratory network and strong biosafety regulatory framework. The Robert Koch Institute (RKI) plays a pivotal role in coordinating national mpox surveillance and confirmatory testing standards, while Germany's advanced life sciences industry supports domestic reagent and instrument manufacturing.

U.K. Monkeypox (mpox) Diagnosis Market Size

The United Kingdom accounts for an estimated 18% share of European mpox diagnostic revenues. The UK Health Security Agency (UKHSA) was among the first authorities globally to scale mpox confirmatory PCR testing in 2022, institutionalizing testing protocols across NHS laboratories. Continued investments in genomic surveillance and response capability are supporting market resilience.

Asia Pacific Monkeypox (mpox) Diagnosis Market Trends and Insights

Asia Pacific is the fast-growing region in the global mpox diagnosis market, driven by the rise in risks of outbreak growing molecular diagnostics infrastructure, and supportive government funding. China is rapidly expanding biosafety level laboratory capacity and local PCR kit manufacturing capability, positioning itself as both a significant consumer and emerging producer of mpox diagnostics. Across the region, post-COVID-19 investments in infectious disease surveillance are accelerating mpox testing preparedness.

India Monkeypox (mpox) Diagnosis Market Size

India is emerging as a priority growth market within Asia Pacific, contributing an estimated 15% of regional mpox diagnostic revenues. The Indian Council of Medical Research (ICMR) designated multiple national reference laboratories for mpox testing, while the domestic diagnostics industry is developing cost-optimized PCR kits to address price-sensitive healthcare procurement environments.

The Monkeypox (Mpox) diagnosis market is characterized by strong competition driven by the growing need for rapid and accurate infectious disease detection. Market participants are focusing on expanding molecular diagnostic portfolios, enhancing test sensitivity and specificity, and developing point-of-care testing solutions to improve outbreak response capabilities. Companies are investing in advanced PCR technologies, automated diagnostic platforms, and innovative assay development to strengthen their market position. Strategic collaborations with public health agencies, regulatory approvals, and increased manufacturing capacity are key competitive strategies.

Key Developments:

• In April 2026, health authorities reported a rapid increase in locally acquired Mpox clade 1b cases in Berlin, with 35 confirmed infections identified since December 2026, including 34 cases linked to local transmission. Genetic sequencing indicated a shared transmission network, highlighting a shift from travel-associated infections to community spread.
• In August 2024, the Andhra Pradesh MedTech Zone (AMTZ), in partnership with Transasia Diagnostics, launched the ErbaMDx MonkeyPox RT-PCR Kit, India's first indigenously developed Mpox diagnostic test. The kit received validation from the Indian Council of Medical Research (ICMR) and emergency authorization from CDSCO.